Company profile
Niki BioSolutions, Inc.
NASDAQ: NIKI · Healthcare · Biotechnology
#946 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
29DFH 51DQ 2GM —SS 10
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, return on assets · ↓ workforce scale, disclosure history
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$1.4M
Employees
1
as of 2026-09-01
Market cap
$558.7k
as of 2026-09-01
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$431.4k$431.4k2023
Net income-$1.4M-$1.4M2025
Total assets$18.7M$18.7M2025
Liabilities$4.9M$4.9M2025
Equity$23.1M$23.1M2025
Revenue trend
FY2023 – FY2023 · USD
FY23
FY23
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Niki BioSolutions, Inc.’s revenue?
Niki BioSolutions, Inc. booked $431.4k in FY2023 revenue, contracting 67% year over year — slower than 85% of Healthcare companies we track, at a -316.0% net margin.
Peers · Healthcare
Integrative Health Technologies, Inc.——Alternate Health Corp.——Scienture Holdings, Inc.50DAequus Pharmaceuticals Inc.——Amarantus BioScience Holdings, Inc.——MediciNova, Inc.41DNeighbors
Mercer →Key facts
CEOChung Yuen Huen
SectorHealthcare
IndustryBiotechnology
HeadquartersPrinceton, NJ
ExchangeNASDAQ: NIKI
Employees1
IPO date2026-07-20
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.